Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when PMVP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsPMV Pharma stockholders elect directors, approve executive pay at 2026 annual meeting
Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read
Key Changes
-
low
Stockholders elected David Mack and Laurie Stelzer as Class III directors for three-year terms through 2029. Stelzer received weaker support with nearly half of votes withheld (10.7M withheld vs 11.3M for).
Item 5.07 verify on EDGAR → -
low
Executive compensation approved on advisory basis with 70% support, but 30% opposition (6.5M against) suggests meaningful shareholder concern about pay levels or structure.
Item 5.07 verify on EDGAR → -
low
Ernst & Young ratified as independent auditor for fiscal 2026 with 98% approval, a routine annual confirmation.
Item 5.07 verify on EDGAR →
Summary
PMV Pharmaceuticals held its 2026 Annual Meeting on June 4, where stockholders voted on standard governance matters. Both director nominees were elected, though Laurie Stelzer's election drew notably weaker support with nearly half of votes withheld, which may signal shareholder concerns about board composition or her qualifications. The advisory vote on executive compensation passed but with 30% opposition, a relatively high level of dissent that suggests some investors are unhappy with how management is being paid.
While non-binding, this level of opposition often prompts companies to engage with shareholders and review compensation practices. For retail investors, these are routine procedural matters with no immediate business impact. However, watch the company's next proxy statement to see if management addresses the compensation concerns or if the board composition changes in response to the tepid support for Stelzer.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
PMV Pharmaceuticals held its 2026 Annual Meeting, electing two Class III directors, approving executive compensation, and ratifying Ernst & Young as auditor.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The Company’s stockholders elected the two persons listed below as Class III Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their respective successors has been duly elected and qualified, or until the earlier of the respective director’s death, resignation or removal. The final voting results are as follows: FOR | WITHHELD | BROKER | NON-VOTE David H. Mack, Ph.D. 15,693,907 | 6,248,461 | 6,975,412 | Laurie Stelzer | 11,261,111 | 10,681,257 | 6,975,412
Stockholders elected David H. Mack and Laurie Stelzer as Class III directors to serve three-year terms until 2029. Mack received 15.7 million votes for versus 6.2 million withheld, while Stelzer received 11.3 million for versus 10.7 million withheld, indicating weaker support for Stelzer.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify